Chemotherapy Drugs for Autoimmune Disease: Why Methotrexate, Cyclophosphamide, and Rituximab Are Used Beyond Cancer

Why are chemotherapy drugs used for autoimmune diseases? Several drugs first developed for cancer calm an overactive immune system when given at much lower doses or on different schedules. Methotrexate, taken once a week at a small fraction of cancer doses, is the preferred first treatment for most people with rheumatoid arthritis. Cyclophosphamide treats severe lupus kidney disease, and rituximab, a lymphoma drug, helps rheumatoid arthritis that resists other treatments. These uses are backed by randomized trials.

Headlines announcing that chemotherapy has moved beyond cancer can make it sound as though drug companies are pushing toxic cancer treatments on people with arthritis or lupus. The reality is more interesting and, for many patients, reassuring. Some of the most effective and inexpensive treatments for autoimmune diseases began as cancer drugs, and decades of research have shown how to use them at doses that control inflammation with manageable side effects. These drugs still require careful monitoring, and dosing errors can be dangerous. This article explains how cancer drugs came to treat autoimmune disease, what trials show about benefits and risks, and how patients can use them safely.

How Did Cancer Drugs End Up Treating Autoimmune Disease?

Cancer and autoimmune diseases share a feature: cells, whether tumor cells or immune cells, multiplying or acting in harmful ways. Drugs that slow cell division or deplete specific immune cells can therefore help both, at different doses. A 2026 review in Pharmacological Reviews by Arduino Mangoni and colleagues notes that methotrexate has been used at high doses as an anticancer agent since the 1940s and later at lower doses in autoimmune diseases. At low doses, its effects appear to involve folate-related blocking of cell division along with other pathways, especially increased release of adenosine, a natural anti-inflammatory signal. In practice, the weekly dose used for arthritis is a tiny fraction of the doses used in cancer treatment, which is why side effects are very different.

Is Methotrexate Effective for Rheumatoid Arthritis?

Yes, and it remains the cornerstone drug. A 2014 Cochrane review by Maria Lopez-Olivo and colleagues analyzed seven randomized trials with 732 people comparing weekly methotrexate (5 to 25 milligrams) with placebo. Based on mainly moderate- to high-quality evidence, methotrexate produced substantial, clinically meaningful improvements over 12 to 52 weeks, including in joint symptoms, pain, and physical function. The trade-off was more side effects: 45 percent of people on methotrexate reported some adverse event at 12 weeks versus 15 percent on placebo, and 16 percent stopped because of side effects versus 8 percent on placebo, with no significant difference in serious adverse events. The 2021 American College of Rheumatology guideline, led by Liana Fraenkel, recommends methotrexate as the preferred initial disease-modifying drug for most adults with moderate to high rheumatoid arthritis activity.

Does Folic Acid Reduce Methotrexate Side Effects?

Yes, and it is standard practice. Because methotrexate interferes with folate, taking folic acid or folinic acid alongside it can prevent some side effects. A 2014 systematic review in The Journal of Rheumatology by Beverley Shea and colleagues pooled six randomized trials with 624 rheumatoid arthritis patients. Folate supplementation reduced nausea, vomiting, and abdominal pain by 26 percent, abnormal liver enzyme rises by about 77 percent, and stopping methotrexate for any reason by about 61 percent, without reducing methotrexate’s effectiveness. Doctors usually prescribe folic acid on the days patients do not take methotrexate.

Why Is Taking Methotrexate Daily Instead of Weekly Dangerous?

Because the body cannot clear repeated daily doses, and toxicity builds quickly. A 2026 multicenter study in Clinical Toxicology by Moss and colleagues reviewed 54 adults reported to six U.S. poison centers after taking oral methotrexate more often than prescribed, almost always daily instead of weekly, for a median of six days. More than half (57 percent) developed organ problems, most often painful mouth sores and low blood counts, and two died. No one developed organ dysfunction if the extra dosing lasted less than three consecutive days. Pharmacists and safety organizations recommend clear weekly labeling, choosing a specific day of the week, and using pill organizers or reminders. Anyone who realizes they have taken extra doses should contact their doctor or poison control immediately.

How Is Cyclophosphamide Used in Lupus?

Cyclophosphamide, a cancer drug that suppresses rapidly dividing immune cells, is used to treat severe lupus nephritis, inflammation of the kidneys that can lead to kidney failure. Older regimens used high monthly doses for long periods, causing serious side effects including infections, infertility, and bladder problems. The Euro-Lupus Nephritis Trial, published in 2002 in Arthritis & Rheumatism by Frédéric Houssiau and colleagues, randomized 90 patients to high-dose or low-dose intravenous cyclophosphamide, both followed by azathioprine. Over about 41 months, treatment failure occurred in 16 percent of the low-dose group and 20 percent of the high-dose group, and kidney remission was achieved in 71 and 54 percent respectively, differences that were not statistically significant, while severe infections were more than twice as frequent in the high-dose group. The trial helped shift practice toward lower cumulative doses, and newer options such as mycophenolate are also used today.

What About Rituximab, a Lymphoma Drug?

Rituximab is an antibody that removes B cells, a type of immune cell. It was first approved for lymphoma, a cancer of B cells, and later found to help autoimmune diseases in which B cells drive inflammation. The REFLEX trial, published in 2006 in Arthritis & Rheumatism by Stanley Cohen and colleagues, randomized 520 people with active rheumatoid arthritis that had not responded to TNF-blocking drugs to one course of rituximab or placebo, both with methotrexate. At 24 weeks, 51 percent of rituximab patients achieved at least 20 percent improvement versus 18 percent on placebo, and 27 versus 5 percent achieved 50 percent improvement, with improvements in fatigue, disability, and quality of life. Most side effects were infusion reactions with the first dose, and the serious infection rate was about 5 per 100 patient-years. Rituximab is also used for certain types of vasculitis and other autoimmune conditions.

Which Other Autoimmune Conditions Use Cancer-Derived Drugs?

Several. Low-dose methotrexate is used for psoriasis, psoriatic arthritis, juvenile arthritis, Crohn’s disease, and some forms of vasculitis and inflammatory eye disease. Azathioprine and mycophenolate, related immune-suppressing drugs, are used in lupus, inflammatory bowel disease, and after organ transplants. Some multiple sclerosis treatments, such as cladribine, were originally developed for blood cancers. In each case, doses and schedules differ from cancer treatment, and the goal is to reset or restrain the immune system rather than destroy a tumor. Newer targeted biologic drugs have joined these older medicines, but the older ones remain important because they work for many patients and are often inexpensive.

What Monitoring Do These Drugs Require?

Regular blood tests are essential. People taking methotrexate usually have blood counts, liver tests, and kidney function checked every few weeks at first and then every few months, because the drug can lower blood cell counts and, rarely, harm the liver or lungs. Alcohol is limited because it adds to liver strain. Methotrexate and cyclophosphamide can cause birth defects or affect fertility, so pregnancy planning and contraception are discussed before starting. Immune-suppressing drugs raise infection risk, so patients are advised to stay current on recommended non-live vaccines and to report fevers promptly. Live vaccines may need to be avoided during treatment.

How Long Does Methotrexate Take to Work?

Usually several weeks. Many people with rheumatoid arthritis notice improvement within 6 to 12 weeks, and full benefit can take a few months, which is why doctors often prescribe a short course of low-dose steroids or anti-inflammatory drugs at the start to control symptoms while methotrexate takes effect. Doses are typically started low and increased over weeks toward an effective level as tolerated. If arthritis remains active after an adequate trial, guidelines suggest adding or switching to other disease-modifying or biologic drugs rather than continuing indefinitely without improvement.

Is Injected Methotrexate Better Than Pills?

For some people, yes. Methotrexate can be taken as weekly tablets or as a weekly injection under the skin, often with a prefilled pen. At higher doses, absorption from tablets becomes less reliable, while injections deliver a more consistent amount. Injections also tend to cause less nausea and stomach upset, so patients who have trouble with tablets or need a higher dose are often switched to injections. Either way, the once-weekly schedule and the need for folic acid and blood monitoring stay the same.

Does Methotrexate Increase Cancer Risk?

This is a common worry. People with rheumatoid arthritis already have a somewhat higher risk of lymphoma than the general population, largely linked to long-standing, active inflammation. Rarely, lymphomas or other lymph node problems develop in people taking methotrexate, and some of these shrink after the drug is stopped, which suggests a role for immune suppression. Overall, studies have not shown that low-dose methotrexate substantially raises cancer risk, and controlling inflammation may itself lower some risks. Patients should report persistent swollen lymph nodes, night sweats, or unexplained weight loss, and skin checks are sensible because immune-suppressing drugs can modestly raise some skin cancer risks.

Who Should Avoid Methotrexate?

Methotrexate is generally avoided in people with significant liver disease, heavy alcohol use, severe kidney impairment, certain blood disorders, and active serious infections, and it must not be used during pregnancy or while trying to conceive. People with existing lung disease need careful evaluation because the drug can rarely cause lung inflammation. For these patients, rheumatologists choose other medicines, such as hydroxychloroquine, sulfasalazine, or biologic drugs, depending on the situation. Because many of these limits involve lifestyle or other health conditions, a full medical history and honest discussion about alcohol use help doctors choose the safest option.

Is Using Cancer Drugs for Arthritis a Win for “Big Pharma”?

Not in the way the headline suggests. Methotrexate is one of the cheapest disease-modifying drugs available, sold as a generic for decades, and guidelines favor it as the first choice partly because it works well at low cost. Expensive biologic drugs are usually reserved for people who do not respond to methotrexate. Rituximab and other biologics are costly, but biosimilar versions have become available and lowered prices in many markets. Concerns about drug company influence are legitimate in many areas of medicine, but in this case, repurposing old cancer drugs has given patients affordable, well-studied options. Questions about cost, access, and marketing are better directed at specific drugs and prices than at the idea of using cancer medicines for autoimmune disease.

Why Do Patients Fear the Word “Chemotherapy”?

Because most people associate chemotherapy with the hair loss, severe nausea, and exhaustion of high-dose cancer treatment. Low-dose methotrexate for arthritis rarely causes those effects; common side effects are mild nausea, fatigue the day after the dose, mouth sores, and slight hair thinning in some people, many of which improve with folic acid or switching to injections. Clinicians often avoid calling it chemotherapy for this reason, while still explaining its cancer origins honestly. Understanding the dose difference helps patients make informed decisions rather than refusing an effective treatment out of fear, or, conversely, underestimating the need for monitoring.

How Do Doctors Choose Between Older Drugs and Biologics?

Treatment usually follows a stepwise approach called treat-to-target. For rheumatoid arthritis, doctors typically start with methotrexate, measure disease activity regularly, and adjust treatment every few months until the disease is in remission or low activity. If methotrexate alone is not enough, options include adding other conventional drugs, such as hydroxychloroquine and sulfasalazine, or adding a biologic such as a TNF blocker or a targeted oral drug. Rituximab is often reserved for people who have not responded to these options or who have specific features, such as a history of lymphoma. Choices depend on disease severity, other health conditions, pregnancy plans, infection risk, cost, insurance coverage, and patient preference, which is why guidelines emphasize shared decision-making between patients and rheumatologists.

How Do These Drugs Compare?

How Can Patients Take Methotrexate Safely?

Take it on the same day each week, and mark that day on a calendar or phone reminder. Confirm with the pharmacist that the label clearly says weekly. Take folic acid as prescribed. Keep scheduled blood tests, even when feeling well. Limit alcohol as advised. Tell every prescriber and pharmacist that you take methotrexate, because some antibiotics, especially trimethoprim-sulfamethoxazole, and some pain relievers can raise methotrexate levels. Report mouth sores, unusual bruising, fever, persistent cough, or shortness of breath promptly. Discuss pregnancy plans in advance, since methotrexate must be stopped months before conception.

Common Myths

“Arthritis patients are getting full chemotherapy.” Weekly low-dose methotrexate is a small fraction of cancer doses.

“These drugs are new and experimental.” Methotrexate has been used for autoimmune disease for decades, backed by randomized trials.

“Cancer drugs for arthritis are a pharma money grab.” Methotrexate is an inexpensive generic and the preferred first choice.

“Side effects are the same as cancer chemotherapy.” Low-dose side effects are usually milder and often reduced by folic acid.

“Missing blood tests is fine if you feel well.” Monitoring catches problems before symptoms appear.

Key Terms

DMARD: Disease-modifying antirheumatic drug, a medicine that slows the underlying disease process.

Methotrexate: A folate antagonist used at high doses for cancer and low weekly doses for autoimmune disease.

Lupus nephritis: Kidney inflammation caused by systemic lupus erythematosus.

B cells: Immune cells that produce antibodies and can drive autoimmune inflammation.

Biosimilar: A highly similar, lower-cost version of an approved biologic drug.

The Bottom Line

Several of the most useful treatments for autoimmune diseases began as cancer drugs. Low-dose weekly methotrexate is the preferred first treatment for most people with rheumatoid arthritis, with trial evidence of substantial benefit and side effects that folic acid helps reduce. Lower-dose cyclophosphamide treats severe lupus nephritis with fewer infections than older high-dose regimens, and rituximab helps rheumatoid arthritis that resists other drugs. These medicines require regular monitoring, and taking weekly methotrexate daily by mistake can be life-threatening. Used correctly, they are well-studied, often inexpensive options rather than a sign of misuse.

Frequently Asked Questions

Is methotrexate for arthritis the same as chemotherapy?

It is the same drug used in some cancer chemotherapy, but at a far lower dose and taken once a week. At these doses it calms inflammation, partly through adenosine signaling, rather than destroying rapidly dividing cells. Side effects are usually much milder than cancer chemotherapy, though regular blood tests are still needed.

How well does methotrexate work for rheumatoid arthritis?

A Cochrane review of seven trials found weekly methotrexate provided substantial, clinically meaningful benefit over placebo in joint symptoms, pain, and function within 12 to 52 weeks. About 16 percent of patients stopped because of side effects, compared with 8 percent on placebo. The American College of Rheumatology recommends it as the preferred first disease-modifying drug for most adults.

Why do I need folic acid with methotrexate?

Methotrexate interferes with folate, which can cause nausea, mouth sores, and liver enzyme rises. A review of six trials found folic or folinic acid reduced stomach side effects by 26 percent, liver enzyme rises by about 77 percent, and stopping treatment by about 61 percent, without reducing methotrexate’s benefit.

What happens if I take methotrexate every day by mistake?

Taking weekly methotrexate daily can cause serious toxicity. In a poison center study, 57 percent of adults who took it daily for a median of six days developed organ problems such as severe mouth sores and low blood counts, and two died. Contact your doctor or poison control immediately if you take extra doses.

Why is a lymphoma drug used for rheumatoid arthritis?

Rituximab removes B cells, which drive both B-cell lymphoma and parts of the inflammation in rheumatoid arthritis. In the REFLEX trial, 51 percent of patients whose arthritis had not responded to TNF blockers improved by at least 20 percent with rituximab, versus 18 percent on placebo. It is used mainly when other treatments have not worked.

References

1. Mangoni AA, Hulin JA, Tommasi S. Recent advances in methotrexate pharmacology and potential therapeutic uses in age-related cardiometabolic and neurodegenerative diseases. Pharmacological Reviews. 2026;78(5):100147. PMID 42470822
2. Lopez-Olivo MA, Siddhanamatha HR, Shea B, et al. Methotrexate for treating rheumatoid arthritis. Cochrane Database of Systematic Reviews. 2014;(6):CD000957. PMID 24916606
3. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis & Rheumatology. 2021;73(7):1108–1123. PMID 34101376
4. Shea B, Swinden MV, Ghogomu ET, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Journal of Rheumatology. 2014;41(6):1049–1060. PMID 24737913
5. Moss M, Liss DB, Chambers AJ, et al. Methotrexate toxicity in the setting of oral therapeutic errors: a multicenter retrospective study. Clinical Toxicology. 2026;64(9):801–807. PMID 42007941
6. Houssiau FA, Vasconcelos C, D’Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis & Rheumatism. 2002;46(8):2121–2131. PMID 12209517
7. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis & Rheumatism. 2006;54(9):2793–2806. PMID 16947627

Last updated: October 10, 2026